{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:27:56Z","timestamp":1788200876465,"version":"build-2803163510"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"crossref","award":["UM1CA221940"],"award-info":[{"award-number":["UM1CA221940"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To quantify how many patients treated for high-grade cervical dysplasia completed guideline-concordant surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients aged 30\u201365 treated for high-grade cervical dysplasia (cervical intraepithelial neoplasia 2 or worse) at two PROSPR II METRICS (Population-based Research to Optimize the Screening Process Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings &amp; Populations sites) (Massachusetts General Brigham, Parkland Health) from 2010 to 2019. The primary outcome was receipt of two negative co-tests after treatment within 30 months (allowing 6-month scheduling leeway).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Among 3,146 patients treated for high-grade dysplasia, most were aged 30\u201339 years (Massachusetts General Brigham 58.9%, Parkland Health 60.9%) and had no or few known comorbidities (Massachusetts General Brigham 81.2%, Parkland Health 85.6%). Race and ethnicity, insurance status, and socioeconomic status reflected broader patient population demographics. Only half of the patients (45.5%) completed two surveillance co-tests after treatment within 30 months (Massachusetts General Brigham 55.3%, Parkland Health 40.6%), among whom a third received at least one subsequent abnormal co-test result (Massachusetts General Brigham 30.9%, Parkland Health 31.6%). Patients who completed two co-tests were under observation longer than those who did not complete two co-tests (median Massachusetts General Brigham 64.9 months vs 33.1 months, median Parkland Health 63.9 months vs 41.8 months). Among patients who completed two co-tests, the timing of surveillance co-testing was largely concordant with guidelines (median [interquartile range] time to first co-test: Massachusetts General Brigham 6.4 [5.1\u20139.2] months, Parkland Health 10.1 [6.6\u201312.6] months; median [interquartile range] time between first and second co-test: Massachusetts General Brigham 8.5 [6.0\u201312.6] months, Parkland Health 12.0 [8.0\u201313.5] months). Overall, 16 patients (0.5%) were diagnosed with cervical cancer after treatment for high-grade dysplasia (median [interquartile range] time from treatment to cancer diagnosis 14.9 [3.8\u201345.9] months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Approximately half of patients did not receive guideline-concordant surveillance after treatment for high-grade dysplasia, and one-third had a subsequent abnormal co-test result. Patients with high-grade cervical dysplasia are at elevated risk of subsequent abnormalities and should continue to be closely monitored. Additional systematic monitoring is needed to ensure guideline-compliant surveillance after dysplasia treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005877","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:00:48Z","timestamp":1741280448000},"page":"461-468","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Guideline-Concordant Surveillance After Treatment for High-Grade Cervical Dysplasia"],"prefix":"10.1097","volume":"145","author":[{"given":"Victoria","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn M.","family":"Lykken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin A.","family":"Tiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca B.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Kobrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/ijc.29971","article-title":"Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study","volume":"138","author":"Skinner","year":"2016","journal-title":"Int J Cancer"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"R4-20260826","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J Low Genit Tract Dis"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/ijc.21604","article-title":"Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia","volume":"118","author":"Soutter","year":"2006","journal-title":"Int J Cancer"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bmj.39363.471806.BE","article-title":"Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study","volume":"335","author":"Strander","year":"2007","journal-title":"BMJ"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"106770","DOI":"10.1016\/j.ypmed.2021.106770","article-title":"Clinical follow-up practices after cervical cancer screening by co-testing: a population-based study of adherence to U.S. guideline recommendations","volume":"153","author":"Perkins","year":"2021","journal-title":"Prev Med"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.gore.2022.101041","article-title":"Increased disparities associated with Black women and abnormal cervical cancer screening follow-up","volume":"42","author":"Boitano","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"R10-20260826","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1158\/1055-9965.EPI-22-0100","article-title":"Evaluating and improving cancer screening process quality in a multilevel context: the PROSPR II Consortium design and research agenda","volume":"31","author":"Beaber","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/ijc.31940","article-title":"Cervical cancer screening research in the PROSPR I Consortium: rationale, methods and baseline findings from a US cohort","volume":"144","author":"Kamineni","year":"2019","journal-title":"Int J Cancer"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"107307","DOI":"10.1016\/j.ypmed.2022.107307","article-title":"Factors associated with timely colposcopy following an abnormal cervical cancer test result","volume":"164","author":"Feldman","year":"2022","journal-title":"Prev Med"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1097\/QAD.0000000000001881","article-title":"Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system","volume":"32","author":"Barnes","year":"2018","journal-title":"AIDS"},{"key":"R14-20260826","doi-asserted-by":"crossref","first-page":"e0183924","DOI":"10.1371\/journal.pone.0183924","article-title":"Effect of cervical cancer education and provider recommendation for screening on screening rates: a systematic review and meta-analysis","volume":"12","author":"Musa","year":"2017","journal-title":"PLoS One"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.pec.2013.08.008","article-title":"Tailored telephone counseling to improve adherence to follow-up regimens after an abnormal Pap smear among minority, underserved women","volume":"93","author":"Miller","year":"2013","journal-title":"Patient Educ Couns"},{"key":"R16-20260826","first-page":"861","article-title":"Development of a text message-based intervention for follow-up colposcopy among predominately underserved Black and Hispanic\/Latinx women","volume":"33","author":"Sansoni","year":"2022","journal-title":"Cancer Causes Control"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"e0274974","DOI":"10.1371\/journal.pone.0274974","article-title":"Racial and ethnic differences in cervical cancer screening barriers and intentions: the My Body My Test-3 HPV self-collection trial among under-screened, low-income women","volume":"17","author":"Zeno","year":"2022","journal-title":"PLoS One"},{"key":"R18-20260826","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:00:36Z","timestamp":1787738436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005877","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"2024-11-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}